CAS 35189-28-7 Norgestimate
19-dinorpregn-4-en-20-yn-3-oneoxime; Norgestimate powder;
Molecular Weight: 369.50
Density: 1.221 g/cm3
Melting Point: 216 ° C
Boiling Point: 497.896 ° C at 760 mmHg
Flash Point: 254.919 ° C
Appearance: White crystalline solid
PackAge: According to the clients requirement
Application: It is an important raw material
Storage: Store in dry, dark and ventilated place.
Norgestimate is a form of progestin, which is a female hormone
important for the regulation of ovulation and menstruation.
Norgestimate is used with estradiol (a female sex hormone that is
involved in the development and maintenance of the female
reproductive system), to treat the symptoms of menopause.
Norgestimate and ethinylestradiol are used as an oral
contraceptive, indicated for the prevention of pregnancy in women.
Norgestimate/ethinyl estradiol is indicated for the prevention of
pregnancy in women who elect to use oral contraceptives as a method
Mifepristone is used for:
Ending pregnancy in women who have been pregnant for 49 days (7
weeks) or less. It may be used with other medicines. If
mifepristone does not work, surgery to end the pregnancy may be
Mifepristone is a synthetic steroide. It works by blocking a
hormone (progesterone) necessary for pregnancy to continue.
How to use mifepristone:
Use mifepristone as directed by your doctor. Check the label on the
medicine for exact dosing instructions.
Mifepristone comes with an extra patient information sheet called a
Medication Guide and a Patient Agreement. Read them carefully. Read
them again each time you get mifepristone refilled.
Mifepristone is supplied by your health care provider and is not
available at a pharmacy.
Mifepristone requires 3 visits to your health care provider.
On day 1 at your health care provider's office, you will read the
Medication Guide and discuss the benefits and risks of using
mifepristone to end your pregnancy. If you decide mifepristone is
right for you, sign the Patient Agreement. After your physical
exam, you will take 3 tablets of mifepristone.
On day 3 at your health care provider's office, if you are still
pregnant, you will take 2 misoprostol tablets. Misoprostol may
cause cramps, nausea, diarrhea, and other symptoms. Your health
care provider may give you other medicines for these symptoms.
Around day 14 at your health care provider's office, you will
return for an important follow-up visit. You must return about 14
days after you have taken mifepristone to be sure the pregnancy has
ended. If the pregnancy has not ended, there is a chance of birth
defects. Your health care provider will discuss with you your
choices, including surgical abortion.
Grapefruit and grapefruit juice may increase the risk of side
effects from mifepristone. Talk to your doctor before including
grapefruit or grapefruit juice in your diet while taking
You must follow the dosing schedule as directed by your doctor. If
you miss an appointment, contact your doctor immediately.
Formulations / Preparations:
Norgestimate is available commercially as a component of a
combination tablet with ethinylestradiol.
(1) Cigarette smoking increases the risk of serious cardiovascular
side effects from oral contraceptive use. This risk increases with
age and with heavy smoking (15 or more cigarettes per day) and is
quite marked in women over 35 years of age. Women who use oral
contraceptives should be strongly advised not to smoke.
(2) Oral contraceptives should not be used in women who currently
have the following conditions: thrombophlebitis or thromboembolic
disorders; a past history of deep vein thrombophlebitis or
thromboembolic disorders; cerebral vascular or coronary artery
disease (current or past history); valvular heart disease with
complications; severe hypertension; diabetes with vascular
involvement; headaches with focal neurological symptoms; major
surgery with prolonged immobilization; known or suspected carcinoma
of the breast or personal history of breast cancer; carcinoma of
the endometrium or other known or suspected estrogen-dependent
neoplasia; undiagnosed abnormal genital bleeding; cholestatic
jaundice of pregnancy or jaundice with prior pill use; acute or
chronic hepatocellular disease with abnormal liver function;
hepatic adenomas or carcinomas; known or suspected pregnancy;
hypersensitivity to any component of this product.
(3) The use of oral contraceptives is associated with increased
risks of several serious conditions including myocardial
infarction, thromboembolism, stroke, hepatic neoplasia, and
gallbladder disease, although the risk of serious morbidity or
mortality is very small in healthy women without underlying risk
factors. The risk of morbidity and mortality increases
significantly in the presence of other underlying risk factors such
as hypertension, hyperlipidemias, obesity and diabetes.